AGWCA
IOVA icon

Annis Gardner Whiting Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Buy
100,470
+70
+0.1% +$266 0.06% 228
2026
Q1 		$352K Buy
+100,400
New +$321K 0.06% 233

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's IOVA Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors increased its Iovance Biotherapeutics (IOVA) stake by 0.07% in Q2 2026, buying an estimated $266 and bringing the position to 100,470 shares worth $418K. The position accounts for 0.06% of the portfolio, ranked #228.

Annis Gardner Whiting Capital Advisors first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors held 100,470 shares of Iovance Biotherapeutics worth $418K as of Q2 2026.
  • Annis Gardner Whiting Capital Advisors bought 70 Iovance Biotherapeutics shares in Q2 2026, an estimated $266.
  • Iovance Biotherapeutics made up 0.06% of Annis Gardner Whiting Capital Advisors's portfolio in Q2 2026, its #228 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.